

# Accepted Manuscript

Title: No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome

Author: J. van Vliet, A. Verrips, A.A. Tieleman, H. Scheffer, H.A. Cats, A.A. den Broeder, B.G.M. van Engelen


PII: S0960-8966(15)30136-X  
DOI: <http://dx.doi.org/doi: 10.1016/j.nmd.2016.03.009>  
Reference: NMD 3166

To appear in: *Neuromuscular Disorders*

Received date: 2-12-2015  
Revised date: 19-2-2016  
Accepted date: 30-3-2016

Please cite this article as: J. van Vliet, A. Verrips, A.A. Tieleman, H. Scheffer, H.A. Cats, A.A. den Broeder, B.G.M. van Engelen, No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome, *Neuromuscular Disorders* (2016), <http://dx.doi.org/doi: 10.1016/j.nmd.2016.03.009>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome

J. van Vliet<sup>1,2</sup>, MD, A. Verrips<sup>1</sup>, MD, PhD, A.A. Tieleman<sup>2</sup>, MD, PhD, H. Scheffer<sup>3</sup>, PhD, H.A. Cats<sup>4</sup>, MD, A.A. den Broeder<sup>4</sup>, MD, PhD, B.G.M. van Engelen<sup>2</sup>, MD, PhD

<sup>1</sup>Department of Neurology, Canisius Wilhelmina Hospital Nijmegen  
P.O. Box 9015, 6500 GS Nijmegen, the Netherlands

<sup>2</sup>Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Medical Centre, Huispost 935

P.O. Box 9101, 6500 HB Nijmegen, the Netherlands

<sup>3</sup>Department of Human Genetics, Radboud University Medical Centre, Huispost 836  
P.O. Box 9101, 6500 HB Nijmegen, the Netherlands

<sup>4</sup>Department of Rheumatology, Sint Maartenskliniek  
P.O. Box 9011, 6500 GM Nijmegen, the Netherlands

### Corresponding author:

Judith van Vliet, MD

Department of Neurology

Canisius Wilhelmina Hospital

P.O. Box 9015, 6500 GS Nijmegen, the Netherlands

e-mail: [judithvanvliet@hotmail.com](mailto:judithvanvliet@hotmail.com), [j.v.vliet@cwz.nl](mailto:j.v.vliet@cwz.nl)

Phone: +31-24-3658765

Email addresses of all co-authors:

[a.verrips@cwz.nl](mailto:a.verrips@cwz.nl)

[Alide.A.Tieleman@radboudumc.nl](mailto:Alide.A.Tieleman@radboudumc.nl)

[Hans.Scheffer@radboudumc.nl](mailto:Hans.Scheffer@radboudumc.nl)

[H.cats@maartenskliniek.nl](mailto:H.cats@maartenskliniek.nl)

[A.denbroeder@maartenskliniek.nl](mailto:A.denbroeder@maartenskliniek.nl)

[Baziel.vanEngelen@radboudumc.nl](mailto:Baziel.vanEngelen@radboudumc.nl)

### Highlights

- Myotonic dystrophy type 2 (DM2) was established in only one out of 398 patients with suspected fibromyalgia (FMS).
- This is not considered to be a relevantly excessive prevalence of DM2 in patients with suspected FMS.
- This implies that patients with suspected FMS should not routinely be tested for DM2.
- The DM2 patient had slight proximal weakness, but no cataract, clinical myotonia or elevated creatin kinase.
- This case demonstrates once again how difficult it can be to establish DM2 as the diagnosis.

Download English Version:

<https://daneshyari.com/en/article/6041108>

Download Persian Version:

<https://daneshyari.com/article/6041108>

[Daneshyari.com](https://daneshyari.com)